Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Give a person a fish and you feed them for a day; teach a person to use the Internet and they won't bother you for weeks.
HAUP $8 +56 new 52wk high eom
HAUP making a nice move!!
Rumor that FORD got a contract to make Apple Iphone covers could be the reason its up.. Just a rumor though.
Wow!! I should go out for lunch more often. I don't see any news.. What's your target? FORD
FORD seems to be dead in the water. How long are you going to wait on this one? Thanks
I hope this amniotic fluid news is good for Geron?? The markets will tell us tomorrow..
Now that you mention it I do remember. Fox cable news reported Apple will be using Cingular and T mobile so they can go worldwide with it. Supposed to combine 3 things, blackberry+ music 5000 titles+ something else that I missed in a much smaller package for around $200.
Anybody know if Sons is connected with Cingular or T mobile. Apple is reported to be launching an I Phone and will announce it at the electronics show in Vegas next week.
GERN-Looks like either way stem cell will get pushed thru.
In campaign commercials in 2006, Democrats and some Republicans boasted of their support for embryonic stem cell research as a way to find treatments for a wide range of diseases. Advocates of such research say that, despite gains in the elections, they still do not have the votes to override a veto. They are working with Senate allies on a plan to attach the stem cell bill to unrelated legislation that Mr. Bush would feel obliged to sign
Sons has 18 mil shares short their gonna have to cover soon..
10 should come easy...
We can only hope SONS performs like AKAM up 171% this year but I doubt SONS sales and profits will keep pace but you never know.
Sons making new 52 wk high
Mr. Primus said the new Congress would also “give the president another chance to veto a stem cell bill,” like the one he vetoed in July.
In campaign commercials in 2006, Democrats and some Republicans boasted of their support for embryonic stem cell research as a way to find treatments for a wide range of diseases. Advocates of such research say that, despite gains in the elections, they still do not have the votes to override a veto. They are working with Senate allies on a plan to attach the stem cell bill to unrelated legislation that Mr. Bush would feel obliged to sign.
There goes $7.50 on haup!!
Hang on HAUP is on its way!!!+71
Why would Merck have options if they knew they couldn't own more than appro 5% of the stock? Do they already own 5%? I would think the lawyers always have a way around it.
From the July announcement it could be Merck funding this round!!
GERON ENTERS INTO A COLLABORATION AND LICENSE AGREEMENT WITH MERCK & CO., INC. FOR CANCER VACCINES TARGETING TELOMERASE
Menlo Park, CA – July 18, 2005 – Geron Corporation (Nasdaq: GERN) announced today it has entered into a collaboration and license agreement with Merck & Co., Inc. (NYSE: MRK) to develop a cancer vaccine targeting telomerase utilizing Merck’s expertise in vaccine technologies.
Under the terms of the agreement, Geron will receive an upfront payment, milestone payments upon achievement of certain development and regulatory events, and royalties. Merck has also agreed to acquire equity in Geron at a future date as part of Geron’s next round of financing. Additional financial terms were not disclosed.
In addition, Merck has acquired an exclusive option to negotiate a separate agreement for Geron’s dendritic cell-based telomerase vaccine currently in Phase I/II clinical trials at Duke University Medical Center. Geron will receive an option payment from Merck in consideration for the option. The structure and terms of an agreement for the dendritic cell vaccine will be negotiated should Merck exercise its rights under the option.
“This alliance reflects Merck’s recognition of telomerase as an important cancer target and Geron’s recognition of the strength of Merck’s vaccine platform,” said Thomas Okarma, M.D., Ph.D., Geron’s president and chief executive officer. “Our decision to collaborate with Merck was an easy one to make. In the course of our discussions, we have been impressed with Merck’s focus and commitment to developing cancer vaccines.”
Geron and Merck have jointly developed a research and development plan to optimize and expedite the demonstration of efficacy and tolerability of a potential vaccine against telomerase using Merck’s platform. Meanwhile, Geron will continue development of its dendritic cell-based vaccine product, which is currently in Phase I/II clinical trials and is the subject of the exclusive option obtained by Merck.
“We at Merck are excited about what Geron has demonstrated with telomerase in cancer. Our objective is to combine our technologies with the hope of bringing a product to market that may have application across a large number of cancers,” said Stephen Friend, M.D., Ph.D., executive vice president, Advanced Technology and Oncology at Merck Research Laboratories. “This is a project of high interest and commitment at Merck, and is indicative of Merck’s strategic direction in developing new anti-cancer therapies.”
GERN is the only stem cell co selling off. This was stick it to the little guy...
$40 mil at 8$- Kind of screwed the little guy on this one. They could have tied it to the most recent stock price!!! Either its going to be a good buying op or were in for long term downward pressure. Lets hope the $8 is supported.
Nice blocks going thru on GERN. We could get another nice run today. Something's up.
Wahz, Where does Neng fall on your list. It looks like it still has great potential.
thanks
NENG- Looked strong today. Could this be a key reversal?
What's your take on HAUP? +75- Time to get out or time to get in??
Thanks
I haup it closes over 5. Volume is ha-up! Next resistance looks to be 5.35
FYI!!
An employee, C. Gray, of the Russell 3000 in interested in hearing comments about the millions of shares that traded late on Friday, June 30th. There is an investigation that has started to try to determine just exactly how the traders depressed the stocks so that they could make millions of low ball trades in the stocks that joined the Russell 3000 in the last minutes of the trading day. Most stocks saw huge volumes in the last minutes at a very depressed price. Anyone who was hurt (is that not all of us?) by this manipulation are invited to write an email to this gentleman. I suggest that you let him know how much it cost you to watch your stock tank just so some other trader could trade at an orchestrated price. I plan to tell him what I saw, how much it hurt my position, and what I think about it.
Russell 3000 does not want stocks in the future to believe that being put on their list is a death nail in their stock price. It is supposed to be a good thing. If the word on the street is to avoid the Russell 3000, it will hurt Russell. Your comments might help Russell to put an end to this practice and might cause some restitution. Take the time to write him today.
The email address is: cgray at russell .com Use the at sign as is normal in email addresses.
Sonus also recently announced a partnership with Atreus Systems that is designed to enable service providers to reduce operating costs and speed the delivery of hosted VoIP services by blending Sonus’ IMS gear with Atreus’ provisioning software for IMS, VoIP and IP service bundles. The goal of the partnership is to deliver a solution that empowers carriers to generate new revenue streams by simplifying the delivery of a suite of value-added consumer and business voice services, including Hosted PBX, business trunking, conferencing, and voice VPN.
The solution has reportedly been selected by an as yet unnamed, large North American carrier as the foundation for its next generation voice network.
Wahz, What's your take on the neng move? Is it still a long term hold?
Thanks,
HAUP Doing well today are do you still have it on your radar? Is this a trend reversal for this stock?
Thanks,
opnion, GERN- How does today's news effect your target of 15-17?
Thanks
Opinion, You still think GERN will make the 15-17 area before mid month?
Thanks
Isn't HAUP oversold now wouldn't this be a good buy area?
GERN--$7.88 Rumor Merix BioScience who owns 10% of (GERN) will buy the rest of company for $15.50 a share. Click below to read more about subscribing to the full JAGnotes product.
Zeev, How does HAUP look to you? Is it a good buy in this area?
Thanks,
Stem Cell News Temperance teen recovers in Portugal
January 10, 2005
BY PATRICIA ANSTETT
FREE PRESS MEDICAL WRITER
LISBON, Portugal -- A tissue sample no bigger than the tip of her baby finger, taken from high inside Cortney Hoffman's nose, holds hope of her recovery from a paralyzing spinal cord injury. The specimen contained more than 2 million adult stem cells, some of the near-magical components of the human body because of their ability to take on tasks of other cells where they are transplanted.
Place them in the heart and they help perform blood-pumping functions.
Put them in a damaged spinal cord like doctors did to Cortney on Saturday and they are believed to take on the Herculean job of sending electrical signals to the brain and back to trigger and to move damaged muscles.
Inserted into the injury site in Cortney's spinal cord by neurosurgeon Dr. Pratas Vital, the cells become the body's molecular jewelry. They even look like small, uncultured pearls, one powerful clump nestled next to each other.
"They look brand new," said Dr. Carlos Lima, chief of the spinal cord autograft team at Lisbon's Hospital de Egas Moniz.
Most important, the cells need to act brand new, creating new nerve cells, neural connections and blood vessels so Cortney, 18, of Temperance can regain some of the sensation and movement she lost two years ago in an auto accident.
Her wish is to walk again. But it will take at least two years of exhaustive rehabilitation to find out just how much recovery she might get from taking a chance on experimental surgery.
Most medical leaders in the field are taking a wait-and-see approach until more results are published. But that hasn't deterred hundreds of people with spinal cord injuries, now booked for the surgery through the end of May.
Cortney's five-hour surgery Saturday was the 37th performed by the team.
Contact PATRICIA ANSTETT at anstett@freepress.com.
http://www.freep.com/news/health/stemcells10e_20050110.htm
GERN-
Rational Investor
In the fourth spot on Hulbert's annual scorecard was Jamie Dlugosch's The Rational Investor, a growth and value letter launched just two years ago. Jamie chose a speculative play on stem cell research for his top pick. Says Jamie, "Notwithstanding the re-election of George W. Bush, stem cell research continues to power forward. My stock of the year, Geron (GERN: news, chart, profile), with 240 stem cell patents, is uniquely positioned to benefit from developments in this exciting area of medical research. Widespread coverage of the stem-cell debate negated nearly 50 percent of GERN's market cap in 2004 and offers investors a chance to scoop up shares at a discount. Earnings are negative, but are expected to show marked improvement in 2005. GERN has tremendous potential."
This was a recap from another website. I have not verified all but have read about most that are stated.
a) SONS announced partnership with Marconi for at least gateways but possibly full product suite. Relationship probably being driven by new business won from BT.
(b) SONS working on at least 3 projects with Motorola in Brazil, Russia, and Bangladesh
(c) SONS announced partnership with giant China Putian for resale of full Sonus product suite into huge Chinese market.
(d) SONS has announced global design, implementation, and support reach via ADC.
(e) SONS is rumored to have won direct business from Vonage. A possible blow to Cisco.
(f) SONS has won new customer netvision.
(g) SONS has announced expanded rollout with Interroute.
(h) Quest and Global Crossing continue to spend big money on SONS equipment. Quest having good success with 150 city one flex rollout for business VoIP. Global Crossing achieves 99.999 reliability with SONS equipment.
(i) Level 3 remains an important customer and continues to win new VoIP business.
(j) Revenue from AT&T 170 city Callvantage rollout will eventually show up. AT&T beginning to offer compelling features to differentiate their VoIP offering.
(k) SONS does have a piece of the Verizon network and will see new revs as it grows.
(l) Vonage has close to 400K subscribers and is adding 10K a month. Vonage partners with Global Crossing who is a SONS customer.
(m) Packet8 is beginning to gain traction with many recently announced retail agreements. Packet8 partners with Level 3 who is a SONS customer.
(n) SONS likely in trials with SBC and Cingular who aquired AT&T wireless who is a SONS customer. Also, Bellsouth who owns a significant stake in Cingular is a SONS customer. Potential for another major win.
(o) SONS has big customer wins in Japan and Mexico. Also, T-systems, IDT, AOL and Time Warner Cable are customers.
(p) India, Europe, and Middle East offer big opportunities for SONS.
(q) SONS quarterly revenue has risen from a low of $3.5 million in 2002 to $46.8 million last quater.
(r) SONS has made $15 million in total PROFIT in the first 3 quaters of 2004.
(s) SONS has over $300 million in cash and only $10 million in debt.
(t) Extensive audit and restatement is completed. Costs associated with Audit should be over and help SONS bottom line.
(u) SONS GSX9000 wins 1999 product of the year.
(v) SONS managment software wins 2000 prodcut of the year.
(w) SONS Insignus softswitch wins 2002 product of the year.
(x) SONS only has 250 million shares compared to billions of shares LU and NT have.
(y) SONS equipment carries 9.5 billion minutes per month of VoIP traffic. SONS is class 4 market leader with 40% market share.
(z) SONS is only softswitch pure play. No revenue ties into rapidly declining legacy switch market
The Microsoft of the stem cell age could be in the making at the Menlo Park offices of the Geron Corp., a 65-employee biopharmaceutical firm that got its start in cancer drug research.
The company's aggressive patenting of embryonic stem cells has given it the early lead in an infant industry that promises to grow substantially over the next decade as California spends up to $3 billion on stem cell research.
At the same time, Geron's emergence fuels skepticism among opponents of the massive state-funded program about lavishing public funds on an enterprise in which one company claims to have a controlling reach.
Since 1996, Geron has invested more than $90 million pioneering the field of human embryonic stem cell research and plans to test its first embryonic stem cell therapy on humans in 2006.
"For the first time," Geron chief executive Thomas Okarma told Wall Street investors in late November, "we have the ability to have a cell therapy product-based business model, where we manufacture, store ... and ship cells for off-the-shelf use."
Proposition 71, passed by 59 percent of voters on Nov. 2, creates the nation's largest stem cell research fund. The vote helped build momentum for Geron, which followed the election with the announcement of a $40 million stock sale, while hailing the publication of studies about the unique potential of its technologies.
Company officials and industry analysts say Geron has few peers worldwide, although competitors are expected to spring up a few years after money from Proposition 71 starts to flow.
"There really isn't much of a stem cell industry," said Joe Panetta, president of BIOCOM, San Diego's biomedical trade group. "It's kind of a stem cell itself."
Human embryonic stem cells have the ability to create healthy new cells and tissues for every part of the body. Supporters say they could help provide cures for such feared ailments as cancer, heart disease and severe burns. The business possibilities are enormous, eventually reaching tens of billions of dollars.
Eighty-two companies worldwide are involved in development of stem cell technologies, according to a 2002 report by the business research firm Kalorama Information.
California firms with at least some stake in stem cells include VistaGen Therapeutics Inc. of Burlingame, StemCells Inc. of Palo Alto, MacroPore Biosurgery Inc. of San Diego and Invitrogen Corp. of Carlsbad.
Kalorama's report said 13 companies were in the best position to capitalize on the emerging technology, but singled out one front-runner: "Geron Corp. is currently the dominant organization in the field," it said.
Geron, first funded in 1992, says only a handful of companies worldwide are doing advanced research on human embryonic stem cells. Other companies mostly are looking at adult stem cells or developing research-related products.
Main Geron competitors have emerged in China, Singapore, Israel and South Korea while the U.S. government discouraged the use of human embryonic stem cells because of ethical concerns: Embryos are destroyed in the process of gathering them.
Industry insiders predict that stem cell business growth over the next five years largely will consist of companies that support Proposition 71 research - for instance, firms that aid the study of stem cells. Once scientists report breakthroughs, look for the formation of more therapeutics outfits.
Exactly how the industry unfolds will be determined partly by the oversight panel governing Proposition 71 money; the panel met for the first time Friday. Among the questions the panel will wrestle with in the coming months include how much of the money will be spent on basic research typically done at universities vs. applied research often handled by companies.
Wayne Johnson, a consultant for the Proposition 71 opposition campaign, said Geron is one of the most likely companies to profit from what he calls "the biggest heist of public funds, probably in the history of the country."
Said Johnson, "This initiative was written very carefully to funnel the money into very specific ... lines of research that are very beneficial to the people who own these patents."
Company President Okarma said before the election that Geron was staying clear of Proposition 71 fund raising. Secretary of state files don't show contributions to the Proposition 71 campaign from Geron, top company officers or its largest stockholders.
Geron's stem cell story started in 1995, when it began funding research into human embryonic stem cells at the University of Wisconsin, Madison, and later at Johns Hopkins University and the University of California, San Francisco.
While federal debates raged about the ethics of stem cell research, Geron kept working - it sponsored the development of the world's first embryonic stem cell colonies - and securing the legal rights to as many of its discoveries as possible.
The company, which also continues to develop anti-cancer drugs, has lost money every year for a total of $255.7 million at the end of 2003 - not an uncommon position in the research-intensive world of biotechnology.
Its investment has generated at least 19 patents worldwide on human embryonic stem cells with 177 pending, the company reported earlier this year. That is believed to be the most extensive intellectual property collection in the industry, covering cells for the liver, heart, bone and nerves.
Today, Okarma says his company is building an intellectual property "fortress" that he hopes will allow Geron to make money whenever and wherever stem cell-based therapies are commercialized.
But Geron's chief financial officer, David Greenwood, said the company isn't trying to stifle competition. To the contrary, he said, Geron aims to stimulate a broad stem cell industry in California.
His approach comes off much softer than Okarma's public statements about the company's "broad, dominating patent estates" and its commitment to "filing of oppositions and interferences against competitors' patents."
Greenwood said Geron is offering its technology free to California university researchers, a common way of getting scientists interested in technologies they otherwise couldn't afford.
But Greenwood also said Geron won't force researchers funded by Proposition 71 money to commercialize new Geron-based products with the company.
Geron still would expect royalties, of course, but Greenwood said researchers could take products to market however they want. "We are quite willing to take this IP (intellectual property) estate and enable others to get into the field," Greenwood said. "I don't spend a lot of time worrying about competitors. I view them as potential partners."
It's the kind of self-help philanthropy the company seems able to afford while its prospects are looking up.
The big break would be if Geron can be the first company to market a stem cell therapy. The company plans human tests of its first stem cell-based product, a treatment for spinal cord injuries, starting in 18 months.
The therapy has proved successful in treating acute spinal cord injuries in rats, which "recover significant motor function" after injection of therapeutic cells, Geron documents say.
At least some Wall Street analysts like Geron's odds. New York investment bank Rodman & Renshaw said in October that it was "pleasantly surprised" that "Geron has made significant strides."
That kind of confidence makes it easier to secure investment for the long road to market. Geron reports having $130 million in cash, but it will have to spend a big chunk of that over the next few years to prove its stem cell therapies work.
GERON CORP.
Headquarters: Menlo Park
President and CEO: Thomas Okarma
Employees: 65
Main business lines: Research-stage cancer and human embryonic stem cell therapies
First funded: 1992
Net loss (2003): $29.9 million
Nasdaq stock ticker: GERN
52-week range: $5.15 to $12.44
Good question. Maybe they specialize stem cell coverage.
GERN..Bloomberg posting at 10:38am........Sandler & Co.initiates coverage on Geron with a 4 page report. Sorry don't have the report.